As India’s pharmaceutical industry braces for the impact of 100 per cent tariffs imposed on the imports of branded and patented pharmaceutical products to the US from October 1, global investment research agencies have said that since generic drugs remain exempt from the US tariffs, there will be no major impact for Indian companies other than Sun Pharma, which has sizeable sales from patented drugs in the US.
Last week, US President Donald Trump dropped another tariff bomb on India when he declared the imposition of 100 per cent tariff on branded or patented drugs entering the United States from October 1, but exempted generic drugs and pharmaceutical companies that build manufacturing plants in the US. This exemption covers projects where construction has already started, including sites that have broken ground or are under construction.
HSBC Global Investment Research said in report that since “generic (off-patent) drugs remain exempt from US tariffs, hence there is no impact for other Indian companies”.
Echoing the sentiment, Anuj Sethi, senior director, Crisil Ratings, said the new tariff “may not significantly hurt Indian drug makers” as exports to the US, which account for 20 per cent of the Indian pharmaceuticals market, primarily comprise generic, off-patent medicines, which may not come within the ambit of these tariffs.
“To be sure, some domestic formulation makers have a niche presence in the branded and patented drugs space, but the contribution of those drugs to their revenue is modest,” he said.
Also Read: ‘Tariffs on Indian pharma would burden American consumers’
He added that given the largely non-discretionary nature of these products, the majority of the tariff cost is likely to be passed through.
“Some of these domestic companies also have manufacturing facilities in the US, which would make them exempt from the new levies,” Sethi said.
HSBC noted, however, that among Indian companies, only Sun Pharma will face some headline risk, that too in a limited capacity.
The agency said Sun Pharma has sizeable sales from patented drugs in the US (about 17 per cent of 2024-25 revenue), with the company reporting global sales of USD 1.217 billion from patented products in FY25, of which the US market accounted for about USD 1.1 billion (85-90 per cent of global sales). This amounted to 17 per cent of total revenue and 8-10 per cent of consolidated EPS in FY25.
“While this tariff development is broadly negative for Sun Pharma, we think the tariff impact on earnings depends on multiple moving parts – spread of supply chain (from active ingredients to Fill-Finish), IP location of the brand, the use of third-party manufacturers, etc. In the worst case, Sun would have to shift manufacturing to CDMO partners with plants in the US,” it said.
Currently, Sun’s patented products are mostly manufactured by global Contract Development and Manufacturing Organisation (CDMO) partners. These include Ilumya, its largest product in the patented portfolio (56 per cent of total patented product sales in FY25); its drug substance testing is done by a CDMO partner based in South Korea; while the finished dose is manufactured by a European CDMO.
HSBC said Sun could also transfer the manufacturing of patented products to its three plants in the US and announce new capex or acquire a manufacturing plant in the US (it has cash of over USD 3 billion as of the June 2025 quarter).
“In any scenario, moving supply chains, tech-transfer, plant re-purposing, etc. would take considerable time (anywhere from 6-24 months) and resources in our view,” it said.
Follow us
